TNF Registered in Europe: Does TNF Get a Second Chance?

Journal of Immunotherapy

Volumn 23, Issue 4, 2000, Pages 505-506

  Eggermont, Alexander M M ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MELPHALAN; TUMOR NECROSIS FACTOR ALPHA;

DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; HUMAN; LIMB PERFUSION; NOTE; PRIORITY JOURNAL; SOFT TISSUE SARCOMA;

ADJUVANTS, IMMUNOLOGIC; ANTINEOPLASTIC AGENTS, ALKYLATING; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COMBINED MODALITY THERAPY; DRUG APPROVAL; EUROPE; HUMANS; LIVER NEOPLASMS; MELPHALAN; SARCOMA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033920493     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-200007000-00015     Document Type: Editorial

References (9)

1. Liènard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992; 10:50-62
2. Eggermont AMM, Schraffordt Koops H, Lienard D, et al. Isolated limb perfusion with high dose tumor necrosis factorα in combination with IFNγ and melphalan for irresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 1996; 14:2653-65
3. Eggermont AMM, Schraffordt Koops H, Klausner JM, et al. Limb salvage by isolated limb perfusion (ILP) with TNF and melphalan in patients with locally advanced soft tissue sarcomas: outcome of 270 ILPs in 246 patients. Proc 35th ASCO, 1999;18:(abstract)2067
4. Van Ijken MGA, van Etten B, de Wilt JHW, van Tiel ST, ten Hagen TLM, Eggermont AMM. Tumor necrosis factor-alpha augments tumor effects in isolated hepatic perfusion with melphalan in a rat sarcoma model. J Immunother 2000:this issue
5. DeWilt JHW, Manusama ER, van Tiel ST, van Ijken MGA, ten Hagen TLM, Eggermont AMM. Prerequisites for effective isolated limb perfusion using tumour necrosis factor-alpha and melphalan in rats. Br J Cancer 1999; 80:161-6
6. DeWilt JHW, ten Hagen TLM, de Boeck G, van Tiel ST, de Bruin EA, Eggermont AMM. Tumour necrosis factor-alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer 2000: 82:1000-3
7. Veen vd AH, Wilt de JHW, Eggermont AMM, van Tiel ST, ten Hagen TLM. TNF-α augments intratumoural concentration of doxorubicin in TNF-α-based isolated limb perfusion in rat sarcoma models and enhances antitumour effects. Br J Cancer 2000; 82:973-80
8. Ten Hagen TLM, Van der Veen AH, Nooijen PTGA, Van Tiel ST, Seynhaeve ALB, Eggermont AMM. Low dose tumor necrosis factor-alpha augments anti-tumor activity of stealth liposomal doxorubicin (DOXIL) in soft tissue sarcoma bearing rats. Int J Cancer, 2000; in press
9. Ruegg C, Yilmaz A, Bieler G, Bamat J, Chaubert P, Lejeune FJ. Evidence for the involvement of endothelial cell integrin αVβ3 in the disruption of the tumor vasculature induced by TNF and IFNγ. Nature Medicine 1998; 4:408-14